| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Supplements |
1 From the Department of Dermatology, University of California, Davis.
In the skin epidermis, the metabolism of polyunsaturated fatty acids (PUFAs) is highly active. Dietary deficiency of linoleic acid (LA), the major 18-carbon n-6 PUFA in normal epidermis, results in a characteristic scaly skin disorder and excessive epidermal water loss. Because of the inability of normal skin epidermis to desaturate LA to 
-linolenic acid, it is transformed by epidermal 15-lipoxygenase to mainly 13-hydroxyoctadecadienoic acid, which functionally exerts antiproliferative properties in the tissue. In contrast, compared with LA, arachidonic acid (AA) is a relatively minor 20-carbon n-6 PUFA in the skin and is metabolized via the cyclooxygenase pathway, predominantly to the prostaglandins E2, F2
, and D2. AA is also metabolized via the 15-lipoxygenase pathway, predominantly to 15-hydroxyeicosatetraenoic acid. At low concentrations, the prostaglandins function to modulate normal skin physiologic processes, whereas at high concentrations they induce inflammatory processes. PUFAs derived from other dietary oils are also transformed mainly into monohydroxy fatty acids. For instance, epidermal 15-lipoxygenase transforms dihomo--linolenic acid (20:3n-6) to 15-hydroxyeicosatrienoic acid, eicosapentaenoic acid (20:5n-3) to 15-hydroxyeicosapentaenoic acid, and docosahexaenoic acid (22:6n-3) to 17-hydroxydocosahexaenoic acid, respectively. These monohydroxy acids exhibit antiinflammatory properties in vitro. Thus, supplementation of diets with appropriate purified vegetable oils, fish oil, or both may generate local cutaneous antiinflammatory and antiproliferative metabolites which could serve as less toxic in vivo monotherapies or as adjuncts to standard therapeutic regimens for the management of inflammatory skin disorders.
Key Words: Arachidonic acid • dihomo--linolenic acid • DGLA • docosahexaenoic acid • DHA • essential fatty acid • eicosapentaenoic acid • EPA • -linolenic acid • GLA • 13-hydroxyoctadecadienoic acid • 13-HODE • 13-HODE-substituted diacylglycerol • leukotriene B4 • LTB4 • prostaglandin E2 • PGE2 • protein kinase C • polymorphonuclear cell • polyunsaturated fatty acid • PUFA
This article has been cited by other articles:
|
|
 |
|
  A. Friedman and S. Moe Review of the Effects of Omega-3 Supplementation in Dialysis Patients Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 182 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. van Gool, C. Thijs, C. J. Henquet, A. C van Houwelingen, P. C Dagnelie, J. Schrander, P. P. Menheere, and P. A van den Brandt {gamma}-Linolenic acid supplementation for prophylaxis of atopic dermatitis--a randomized controlled trial in infants at high familial risk Am. J. Clinical Nutrition, April 1, 2003; 77(4): 943 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Serhan, S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R.-L. Moussignac Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals J. Exp. Med., October 21, 2002; 196(8): 1025 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. MADANI, A. HICHAMI, A. LEGRAND, J. BELLEVILLE, and N. A. KHAN Implication of acyl chain of diacylglycerols in activation of different isoforms of protein kinase C FASEB J, December 1, 2001; 15(14): 2595 - 2601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Liu, D. M. Bibus, A. M. Bode, W.-Y. Ma, R. T. Holman, and Z. Dong Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and cell transformation in JB6 cells PNAS, June 19, 2001; 98(13): 7510 - 7515. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
